Heat Shock Protein Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Heat Shock Protein (HSP) Inhibitors are a class of therapeutic agents that target heat shock proteins, which play a crucial role in cellular stress response and protein folding. These inhibitors disrupt the chaperone function of HSPs, leading to the degradation of oncoproteins and induction of tumor cell death. HSP inhibitors are being investigated for various disease indications, including cancer, neurodegenerative diseases, and autoimmune disorders. According to WHO, cancer is a leading cause of mortality worldwide, with an estimated 10 million deaths in 2020. In Europe, cancer accounts for approximately 25% of all deaths, and the incidence is expected to increase by 20% by 2030. In the USA, cancer affects millions of individuals, with lung, breast, and colorectal cancers being the most common. Neurodegenerative diseases, such as Alzheimer's and Parkinson's, are a significant health burden in Europe and the USA.

The growth of the Heat Shock Protein Inhibitor market is driven by several factors. These include the increasing prevalence of cancer and neurodegenerative diseases, advancements in drug discovery technologies, and a growing emphasis on targeted therapies and personalized medicine. Furthermore, collaborations between pharmaceutical companies, academic institutions, and research organizations contribute to the development of novel HSP inhibitors and their successful translation into clinical applications. Companies such as Aldeyra, Bms, Ligand, Revalesio, Otsuka, Esanex, Infinity Pharma, Achieve Life Sciences, Imara, Madrigal Pharma, Minneamrita Therap, Nitto Denko, Samus Therap, Nighthawk Biosci, N-Gene, Regranion, Exelixis, Capstone, Tarveda Therap, Csl Behring cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Otsuka is currently conducting a clinical trial of the drug AT13387 for the treatment of idiopathic breast neoplasms.

Heat Shock Protein Inhibitor Market Key Developments

• In May 2022, the developer of IMR 26, Enliven Therapeutics merged with Imara Inc
• In April 2023, Bristol-Myers Squibb’s BMS 986263 entered into phase II trials for Idiopathic-pulmonary-fibrosis in the USA, Germany, Japan, and the UK 

Approved Heat Shock Protein Inhibitor molecules

• Minnelide
• Icapamespib (PU-AD)
• Jeselhy (pimitespib)
• Gamitrinib

Heat Shock Protein Inhibitor Pipeline Molecules

• Aldeyra
• Bms
• Ligand
• Revalesio
• Otsuka
• Esanex
• Infinity Pharma
• Achieve Life Sciences
• Imara
• Madrigal Pharma
• Minneamrita Therap
• Nitto Denko
• Samus Therap
• Nighthawk Biosci
• N-Gene
• Regranion
• Exelixis
• Capstone
• Orphazyme
• Bold Therap
• Innate
• J Ints Bio
• Kyowa Kirin
• Patrys
• Reata
• Tarveda Therap
• CSL Behring
• Complexa
• Daiichi Sankyo
• Ai Therap
• Sino Biopharm
• Resprotect
• Hillhurst Biopharma
• Fox Chase Cancer Center
• National Cancer Institute
• Inc
• Sciclone
• Merck (Msd)
• Zevra Therap
• Intezyne
• National Cancer Institute - Bethesda
• Redhill
• The Wistar Institute
• Roswell Park Comprehensive Cancer Center

Clinical Activity and Development of Heat Shock Protein Inhibitor

In the Heat Shock Protein Inhibitor space, more than 30 companies are conducting more than 500 clinical trials in this category of drugs. For instance,

• In April 2021, Imara Pharmaceuticals presented pharmacodynamics data of IMR 261 at the 27th Congress of the European Haematology Association (EHA-2022)
• In August 2020, National Cancer Institute completed a phase I trial of Onalespib in Solid tumors (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in the USA.